Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

aflibercept, while key secondary endpoints included safety, mean changes in best corrected visual acuity and central subfield thickness (CST), and change in Diabetic Retinopathy Severity Scale ...

and change in diabetic retinopathy severity scale (DRSS) over time. According to the interim results reported last October, Duravyu 2.7mg demonstrated an early, sustained, and clinically ...

The trial’s primary efficacy endpoint was the percentage of subjects achieving a two-step or greater improvement on the DR Severity Scale ... or progression of diabetic retinopathy.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

All subjects who received AXPAXLI showed diabetic retinopathy severity scale (DRSS) improvement or stability, while any worsening of DRSS occurred only in sham-treated subjects. Arshad M.

All subjects who received AXPAXLI showed diabetic retinopathy severity scale (DRSS) improvement or stability, while any worsening of DRSS occurred only in sham-treated subjects. Arshad M.

All subjects who received AXPAXLI showed diabetic retinopathy severity scale (DRSS) improvement or stability, while any worsening of DRSS occurred only in sham-treated subjects. Arshad M. Khanani, MD, ...